Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTPH.L Regulatory News (MTPH)

  • There is currently no data for MTPH

Statement regarding Price Movement

1 May 2020 11:08

RNS Number : 6700L
Midatech Pharma PLC
01 May 2020
 

1 May 2020

 

Midatech Pharma PLC

("Midatech" or the "Company")

 

Statement regarding Price Movement

 

 

Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines notes the recent movement in its share price and the Company confirms that it knows of no operational or corporate reason for the share price move.

 

As noted in the Company's recent announcements on 20 April 2020 and 31 March 2020 regarding the Company's strategic review, the Company continues in its Formal Sale Process and confirms that there are no material updates following those announcements.

 

The Company expects to announce its full year results for the year ended 31 December 2019 by the end of June 2020.

 

 

Midatech Pharma PLC

Stephen Stamp, CEO, CFO

Tel: +44 (0)1235 888300

www.midatechpharma.com

Panmure Gordon (UK) Limited (Nominated Adviser and Broker)

Freddy Crossley, Emma Earl (Corporate Finance)

James Stearns (Corporate Broking)

Tel: +44 (0)20 7886 2500

IFC Advisory Limited (Financial PR and UK Investor Relations)

Tim Metcalfe / Graham Herring

Tel: +44 (0)20 3934 6630

Email: midatech@investor-focus.co.uk

Edison Group (US Investor Relations)

Joseph Green/ Laine Yonker

Tel: (646) 653-7030/ 7035

jgreen@edisongroup.com/ lyonker@edisongroup.com

 

 

Publication on website

A copy of this announcement will be made available (subject to certain restrictions relating to persons resident in restricted jurisdictions) on the Company's website at www.midatechpharma.com in accordance with Rule 26.1 of the Code by no later than 12 noon (London time) on 21 April 2020. For the avoidance of doubt, the content of the website referred to in this announcement is not incorporated into and does not form part of this announcement.

Disclosure requirements of the Code

Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any securities exchange offeror is first identified. An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 pm (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 pm (London time) on the 10th business day following the announcement in which any securities exchange offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.

Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1% or more of any class of relevant securities of the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s), save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 pm (London time) on the business day following the date of the relevant dealing.

If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.

Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).

Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Takeover Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. You should contact the Takeover Panel's Market Surveillance Unit on +44 (0)20 7638 0129 if you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure.

Additional information

Panmure Gordon (UK) Limited ("Panmure"), is authorised and regulated by the Financial Conduct Authority in the United Kingdom. Panmure is acting as financial adviser in relation to the Takeover Code exclusively for Midatech and no one else in connection with the matters set out in this announcement and will not regard any other person as its client in relation to the matters set out in this announcement and will not be responsible to anyone other than Midatech for providing the protections afforded to clients of Panmure or its affiliates, or for providing advice in relation to the contents of this announcement or any other matter referred to herein.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
SPMSSMFSFESSESI
Date   Source Headline
20th Dec 20177:00 amRNSMidatech initiates Gelclair Phase IV trial
22nd Nov 20177:00 amRNSMidatech receives manufacturing certification
7th Nov 20179:35 amRNSIssue of Equity for Midatech Share Incentive Plan
19th Oct 201710:52 amRNSHolding(s) in Company
19th Oct 20179:44 amRNSHoldings in Company
16th Oct 201712:44 pmRNSResult of General Meeting
28th Sep 20172:35 pmRNSResult of Placing to raise £6m & PDMR Shareholding
28th Sep 20177:01 amRNSInterim Results 2017
28th Sep 20177:00 amRNSProposed Placing and Open Offer
21st Sep 20179:00 amRNSHolding(s) in Company
7th Sep 20177:00 amRNSNotice of interim results
4th Sep 20177:00 amRNSMidatech submits MTD201 CTA filing
25th Aug 20171:59 pmRNSHolding(s) in Company
26th Jul 20177:00 amRNSCompletion of pre-clinical liver cancer programme
18th Jul 20177:00 amRNSTrading Update and Notice of Results
13th Jun 20177:00 amRNSSite visit for investors and analysts
7th Jun 20177:00 amRNSMidatech signs global agreement for panobinostat
22nd May 20177:00 amRNSProgress update on brain cancer therapies
19th May 20173:12 pmRNSIssue of Equity for Midatech Share Incentive Plan
3rd May 20172:30 pmRNSResult of AGM
4th Apr 20177:02 amRNSFinancial results for year ended 31 December 2016
14th Mar 20177:00 amRNSNotice of Results
10th Mar 20177:00 amRNSMidatech Announces Initial Scale-Up of Facility
27th Feb 20177:00 amRNSMidatech enters into Loan Agreement with SVB
20th Jan 201711:05 amRNSSecond Price Monitoring Extn
20th Jan 201711:00 amRNSPrice Monitoring Extension
20th Jan 20177:00 amRNSTrading Update
20th Dec 201612:56 pmRNSDirector/PDMR Shareholding
15th Dec 20164:31 pmRNSHolding(s) in Company
22nd Nov 20167:00 amRNSMidatech receives upfront on Emergex vaccine deal
15th Nov 20167:00 amRNSMidatech selects MTR104 for liver cancer treatment
2nd Nov 201612:57 pmRNSHolding(s) in Company
2nd Nov 20169:51 amRNSHolding(s) in Company
28th Oct 201611:12 amRNSResult of GM, Open Offer & Issue of Equity
11th Oct 20162:59 pmRNSResults of Placing to raise £16.0 million
11th Oct 201611:18 amRNSProposed Placing and Open Offer
30th Sep 20167:00 amRNSFirst in Human Immunotherapy Study Start
21st Sep 20167:00 amRNSMidatech Pharma US Partnership with R-Pharm US
2nd Sep 20167:00 amRNSInterim Results
10th Aug 20167:00 amRNSTrading Update and Notice of Results
7th Jul 20168:15 amRNSMidatech receives grant funding
30th Jun 20161:11 pmRNSAnnual Report Posting
27th Jun 20167:00 amRNSIssue of Equity and Director's Dealings
18th May 20167:00 amRNSMidatech Pharma announces clinical pipeline update
11th May 20165:28 pmRNSResult of AGM
11th May 20167:00 amRNSAGM Statement and Update on Trading
26th Apr 20167:00 amRNSMidatech announces positive Q-Octreotide data
21st Apr 20167:00 amRNSPositive data for OpsiSporin Uveitis programme
13th Apr 20167:00 amRNSFinancial results for the year ended 31 Dec 2015
11th Apr 20167:00 amRNSCommercial Launch of Zuplenz® (Ondansetron) in US

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.